{
    "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity",
    "pmid": "38216550",
    "pmcid": "PMC10786722",
    "study_parameters": [
        {
            "Study Parameters ID": 1452352264,
            "Variant Annotation ID": 1452352260,
            "Study Type": null,
            "Study Cases": 855.0,
            "Study Controls": null,
            "Characteristics": "plasma dihydrouracil/uracil",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.05",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": "1452352260"
        },
        {
            "Study Parameters ID": 1452352360,
            "Variant Annotation ID": 1452352325,
            "Study Type": null,
            "Study Cases": 1055.0,
            "Study Controls": null,
            "Characteristics": "plasma dihydrouracil/uracil",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.01",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": "1452352325"
        },
        {
            "Study Parameters ID": 1452352324,
            "Variant Annotation ID": 1452352320,
            "Study Type": null,
            "Study Cases": 1265.0,
            "Study Controls": null,
            "Characteristics": "plasma dihydrouracil/uracil",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.01",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": "1452352320"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
        {
            "Variant Annotation ID": 1452352260,
            "Variant/Haplotypes": "rs56038477",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).\" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].",
            "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "1452352260"
        },
        {
            "Variant Annotation ID": 1452352325,
            "Variant/Haplotypes": "rs1801160",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "The association between common DPYD genetic variants (MAF ≥ 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
            "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "1452352325"
        },
        {
            "Variant Annotation ID": 1452352320,
            "Variant/Haplotypes": "rs2297595",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "The association between common DPYD genetic variants (MAF ≥ 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
            "Sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.",
            "Alleles": "CC + CT",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "1452352320"
        }
    ]
}